Crinetics Pharmaceuticals, Inc.
CRNX
$46.98
$1.974.38%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 1.54M | 1.39M | 760.00K | 1.04M | 1.04M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.54M | 1.39M | 760.00K | 1.04M | 1.04M |
| Cost of Revenue | 246.37M | 217.81M | 216.20M | 193.30M | 172.32M |
| Gross Profit | -244.83M | -216.42M | -215.44M | -192.26M | -171.28M |
| SG&A Expenses | 165.81M | 139.44M | 114.44M | 99.74M | 88.64M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 479.38M | 424.45M | 377.49M | 339.89M | 307.81M |
| Operating Income | -477.85M | -423.06M | -376.73M | -338.85M | -306.77M |
| Income Before Tax | -423.10M | -369.83M | -328.25M | -298.41M | -277.91M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -423.10 | -369.83 | -328.25 | -298.41 | -277.91 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -423.10M | -369.83M | -328.25M | -298.41M | -277.91M |
| EBIT | -477.85M | -423.06M | -376.73M | -338.85M | -306.77M |
| EBITDA | -474.16M | -419.62M | -373.49M | -336.07M | -304.51M |
| EPS Basic | -4.53 | -4.11 | -3.82 | -3.70 | -3.72 |
| Normalized Basic EPS | -2.83 | -2.57 | -2.39 | -2.31 | -2.32 |
| EPS Diluted | -4.53 | -4.11 | -3.82 | -3.70 | -3.72 |
| Normalized Diluted EPS | -2.83 | -2.57 | -2.39 | -2.31 | -2.32 |
| Average Basic Shares Outstanding | 372.60M | 358.48M | 343.70M | 322.88M | 298.53M |
| Average Diluted Shares Outstanding | 372.60M | 358.48M | 343.70M | 322.88M | 298.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |